Kristagen
Research OnlyA synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
EDG · Glu-Asp-Gly · Immune tripeptide
Mostly preclinical · 2 human studies
- Preclinical
- 67%
- Clinical
- 17%
Based on 12 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 22: best human-relevant evidence is uncontrolled single-group Russian observational reporting; EDG-specific data is animal/in-vitro (1A=9, high RoB 1B=4, N<50 1C=2, indirect/adjacent-peptide 1D=3) with a modest preclinical program on related Khavinson peptides (1E=4). Mechanism 30: target inferred via the gene-promoter bioregulator framework but no measured binding/knockout for EDG (2A=10); proximal signaling partially mapped for the class (sphingomyelin pathway PMID:12420072, IFN-gamma promoter PMID:23289226 for the AEDG tetrapeptide) (2B=10); little EDG dose-response (2C=4); in-vitro plus class-level in-vivo (2D=6). Plausibility 61: immune/thymic claims cohere with immunosenescence biology and same-class analogues (Thymalin, Vilon) but rest on >=1 unproven intermediate link and EDG-specific activity inferred from the class (3A=16, 3B=19, 3C=14, 3D=12). Global Coverage 17: research concentrated in one Khavinson-linked group, ~one country, <5 EDG-specific studies, no governance approval (4A=5, 4B=7, 4C=5, 4D=0). Community Experience 18: negligible documented real-world use, no consistent reports, no notable adverse signal over minimal exposure (5A=4, 5B=5, 5C=3, 5D=6). Effectiveness not established: no quantified human efficacy estimate and no meaningful community effect signal. Citation note: cited PMIDs all resolve to real St. Petersburg Institute / Khavinson papers, but most test adjacent peptides (AEDG/Epitalon, Vilon, Thymalin), not EDG directly.
The proposed mechanisms of Kristagen are based entirely on Russian bioregulator research. No independent Western validation or controlled human studies exist.
How It Works (Simplified)
Kristagen is claimed to target immune system regulation through thymus-related pathways:
Claimed to bind to thymic tissue and modulate gene expression in thymocytes, supporting T-cell maturation and thymic function.
Proposed to influence the differentiation pathways of immune cells, affecting T-cell and B-cell development and ratios.
Claimed to influence cytokine production and balance, potentially normalizing immune response patterns in aged individuals.
Based on Khavinson’s bioregulator theory that short peptides can restore organ-specific gene expression patterns disrupted by aging.
Note: These pathways are proposed based on Russian bioregulator theory. No independent Western research has validated these mechanisms.
Important Limitations
- 100% of research from Russian institutes (St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any claims
- No controlled human clinical trials exist
- Bioregulator peptide theory remains controversial in mainstream immunology
- Pharmacokinetics, optimal dosing, and bioavailability in humans not characterized
- Comparison to validated immunomodulators like Thymosin-alpha-1 shows significant evidence gap
- Safety profile in humans not established through rigorous trials
Based on preclinical data: Initial effects on immune cell gene expression may begin. Russian protocols suggest early changes in lymphocyte activity. No human pharmacokinetic data available.
PMID:22238759Continued treatment in animal models shows progressive effects on thymic function. Cytokine modulation reported in early treatment phases. Human response timeline is unknown.
PMID:23289226Russian studies report observable changes in immune parameters after several weeks of treatment. Lymphocyte subpopulation changes noted in observational studies.
PMID:22803057Long-term effects based on Russian observational studies. Cyclical treatment protocols often used (10-20 days on, rest periods). Optimal duration and long-term safety in humans are unknown.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Thymalin
CompatibleBoth target thymus function - Kristagen as a synthetic tripeptide, Thymalin as a thymic extract. May have overlapping immunomodulatory mechanisms.
Vilon
CompatibleFellow Russian bioregulator peptide targeting immune function. Vilon (Lys-Glu) and Kristagen (Glu-Asp-Gly) have distinct sequences with potentially complementary effects.
Thymosin-Alpha-1
CompatibleBoth immunomodulatory peptides - Ta1 with extensive Western clinical validation, Kristagen with only Russian preclinical data. Different mechanisms of immune support.
Epithalon
CompatibleBoth Khavinson bioregulator peptides - epithalon for telomerase/longevity, Kristagen for immune modulation. No known contraindications.
BPC-157
CompatibleDifferent targets - BPC-157 for tissue healing, Kristagen for immune regulation. No known interactions.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Kristagen
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin · hCAP18 · Human Cationic Antimicrobial Peptide 18 +3
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymogen
Glu-Trp · EW dipeptide · Timogen +2
A synthetic dipeptide (glutamyl-tryptophan) developed in Russia as a defined successor to thymalin. Approved in Russia for immunomodulation with extensive Russian clinical literature. Represents an attempt to create a standardized, synthetic thymic peptide. Not approved by Western regulatory agencies.